# Liver Function Tests

Interpret liver biochemical tests by injury pattern, bilirubin fractionation, and synthetic function; rapidly identify acute liver failure or obstruction, confirm persistent abnormalities, and direct targeted evaluation for hepatocellular, cholestatic, metabolic, congestive, and drug-related disease.

**Clinical question:** How should physicians classify and act on abnormal liver biochemical tests to identify urgent disease and guide etiologic evaluation?

Updated: 2026-09-16T01:18:32.260607+00:00

## What matters in practice
- Separate markers of hepatocellular injury (ALT, AST), cholestasis or infiltration (alkaline phosphatase, bilirubin), and hepatic synthetic function (prothrombin time, albumin) before pursuing an etiologic workup. [7][10]
- Marked aminotransferase elevations greater than 15 times the upper limit of normal should immediately redirect the differential toward acute viral hepatitis, drugs or toxins, ischemic hepatitis, autoimmune hepatitis, Wilson disease, acute biliary obstruction, or acute hepatic vascular disease. [10]
- When aminotransferases exceed 3 times the upper limit of normal or total bilirubin exceeds 2 times the upper limit of normal, prompt repeat testing is particularly important because deterioration may herald a severe drug-induced reaction. [1]
- In right-sided heart failure, bilirubin and alkaline phosphatase elevation with only mild AST and ALT elevation supports congestive hepatopathy; fibrosis-4 and APRI correlate poorly with hepatic disease severity in this setting. [5]
- For patients with cardiometabolic risk factors, abnormal liver enzymes, or imaging-detected steatosis, sequential fibrosis assessment with FIB-4 followed by transient elastography is used to identify advanced fibrosis risk. [9]

## Identify liver failure and severe acute injury before outpatient evaluation

Abnormal tests require escalation when injury is accompanied by impaired hepatic function or rapid biochemical progression.

Order or review ALT, AST, alkaline phosphatase, total and direct bilirubin, prothrombin time, and albumin together when assessing clinically meaningful liver abnormalities. ALT and AST primarily indicate hepatocellular damage; alkaline phosphatase suggests cholestatic or infiltrative disease; bilirubin may reflect cholestasis, impaired conjugation, or biliary obstruction; prothrombin time and albumin contribute to assessment of hepatic function. [7][10]

Treat acute liver failure as a critical-care and transplant-center problem. It is dynamic, can require organ support and early liver transplantation, and management must include rapid cause identification plus active prevention and treatment of complications such as intracranial hypertension and sepsis. Therapeutic plasma exchange and, in some centers, early renal replacement therapy are established components of care; artificial liver devices other than these approaches lack supporting evidence for routine practice. [18]

Use the magnitude of aminotransferase elevation to narrow urgency. ALT or AST elevations greater than 15 times the upper limit of normal are associated with acute viral hepatitis, medications or toxins, ischemic hepatitis, autoimmune hepatitis, Wilson disease, acute bile duct obstruction, acute Budd-Chiari syndrome, or hepatic artery ligation; evaluate these branches without deferring assessment to serial routine monitoring. [10]
- Escalate urgently when abnormal liver biochemistries coexist with impaired hepatic function, because the urgency of evaluation rises with the degree of biochemical abnormality. [7]
- In a potential drug-induced liver injury, repeat liver tests promptly when aminotransferases are greater than 3 times the upper limit of normal and/or total bilirubin is greater than 2 times the upper limit of normal. [1]
- Do not use a single repeat test to reassure when symptoms persist or values worsen; continuing exposure may permit progression of a severe reaction. [1]

*High-yield test patterns that change the immediate differential. [7][10]*

| Pattern | Primary interpretation | Immediate diagnostic direction |
| --- | --- | --- |
| ALT and AST elevation | Hepatocellular damage. [7][10] | If greater than 15 times the upper limit of normal, evaluate acute viral, toxic or drug-related, ischemic, autoimmune, Wilson, obstructive, and vascular causes. [10] |
| Alkaline phosphatase elevation | Cholestatic or infiltrative process. [10] | Assess bilirubin and pursue a biliary or infiltrative disease branch. [10] |
| Bilirubin elevation | Cholestasis, impaired conjugation, or biliary obstruction. [10] | Fractionate bilirubin and interpret with alkaline phosphatase and aminotransferases. [10] |
| Prolonged prothrombin time or low albumin | Potential impaired hepatic synthetic function. [7] | Assess for acute liver failure or advanced chronic liver disease and determine need for urgent higher-level care. [7][18] |

## Classify hepatocellular, cholestatic, and mixed biochemical injury

The dominant abnormality determines the most efficient next diagnostic branch.

A hepatocellular pattern is ALT- and AST-predominant. For mild aminotransferase elevations below 5 times the upper limit of normal, the differential differs according to whether ALT or AST predominates; persistent abnormalities warrant etiologic evaluation rather than attributing the result to metabolic disease solely from the presence of obesity or diabetes. [10]

A cholestatic or infiltrative pattern is alkaline-phosphatase predominant, often with bilirubin elevation. Interpret bilirubin in this setting as a potential marker of cholestasis or obstruction, then determine whether the clinical trajectory suggests acute obstruction, chronic cholestatic disease, infiltrative disease, or congestion. [10]

A mixed pattern should retain both branches in the differential. Avoid assigning causality from a single analyte: aminotransferase elevations reflect injury rather than hepatic reserve, whereas prothrombin time and albumin help assess functional impairment. [7][10]
- Confirm that an alkaline phosphatase abnormality is being interpreted as a potential cholestatic or infiltrative signal rather than as isolated proof of hepatocellular injury. [10]
- Interpret total bilirubin with direct fractionation because bilirubin abnormalities may arise from cholestasis, impaired conjugation, or obstruction. [10]
- Use the time course and prior values to distinguish new acute injury from chronically altered liver biochemistry; persistent abnormalities and ultrasound-detected steatosis have been used as triggers for fibrosis-oriented assessment. [2]

*Biochemical pattern recognition for targeted evaluation. [7][10]*

| Dominant test abnormality | What it indicates | Etiologies requiring priority consideration |
| --- | --- | --- |
| ALT/AST predominant | Hepatocellular damage. [7][10] | At marked elevations: acute viral hepatitis, medications or toxins, ischemic hepatitis, autoimmune hepatitis, Wilson disease, acute obstruction, and acute Budd-Chiari syndrome. [10] |
| Alkaline phosphatase predominant | Cholestatic or infiltrative disease. [10] | Biliary obstruction, chronic cholestatic disease, infiltrative processes, and congestive hepatopathy. [5][10] |
| Bilirubin predominant | Cholestasis, impaired conjugation, or biliary obstruction. [10] | Use bilirubin fractionation and accompanying enzyme pattern to select the next branch. [10] |
| Abnormal prothrombin time or albumin with injury markers | Possible functional hepatic impairment. [7] | Acute liver failure or advanced chronic liver disease requires expedited assessment. [18] |

## Direct testing by the most likely etiologic branch

History, medication exposure, cardiometabolic risk, and hemodynamics should change the testing sequence.

For marked hepatocellular injury, obtain exposure and chronology data before labeling the process idiopathic: prescribed drugs, over-the-counter agents, herbal or dietary supplements, toxins, hypotensive episodes, viral risk, and autoimmune context directly determine the priority differential. Acute viral hepatitis, medications or toxins, ischemic hepatitis, autoimmune hepatitis, Wilson disease, acute bile duct obstruction, and acute Budd-Chiari syndrome are recognized causes of severe aminotransferase elevation. [10]

For suspected drug-induced liver injury, stop or reconsider the implicated exposure according to clinical severity and monitor aminotransferases, total bilirubin, and alkaline phosphatase closely. FDA guidance emphasizes prompt retesting when aminotransferases are markedly abnormal or bilirubin is elevated, because a delay may allow progression when the initial abnormality is the herald of a severe reaction. [1]

For metabolic dysfunction-associated steatotic liver disease, establish steatosis and at least one cardiometabolic risk factor while accounting for alcohol exposure and competing liver diseases. MASLD is defined by steatosis with one or more cardiometabolic risk factors in the absence of harmful alcohol intake; terminology now replaces NAFLD with MASLD and NASH with MASH. [9][12][15]
- In cardiometabolic-risk patients with abnormal enzymes or radiologic steatosis, use a blood-based fibrosis score such as FIB-4, then transient elastography for sequential advanced-fibrosis risk assessment. [9]
- Do not treat normal aminotransferases as exclusion of clinically important chronic liver disease; biochemical injury markers and fibrosis risk are distinct clinical questions. [8][9]
- Screen alcohol exposure in at-risk patients during liver evaluation; alcohol and metabolic dysfunction frequently coexist and may jointly contribute to chronic liver disease. [15][16]

### Metabolic steatotic liver disease

In MASLD, fibrosis risk—not aminotransferase magnitude alone—determines the need for further staging. A stepwise pathway using FIB-4 followed by transient elastography is suitable to rule out or identify advanced fibrosis, which predicts liver-related outcomes. [9]

Management should target metabolic disease in parallel with liver risk: lifestyle modification, weight loss, dietary change, exercise, alcohol reduction, and optimization of comorbidities are recommended. Incretin-based therapy such as semaglutide or tirzepatide may be used when indicated for type 2 diabetes or obesity; bariatric surgery is an option in appropriate patients. [9]
- MASH denotes steatosis with inflammation and hepatocyte ballooning and is the progressive inflammatory form of MASLD. [13]
- Evaluate cardiovascular, diabetes, and kidney risk alongside liver disease because MASLD is linked with cardiovascular disease, type 2 diabetes, chronic kidney disease, cirrhosis, liver failure, and hepatocellular carcinoma. [3]

### Congestive hepatopathy

In right-sided heart failure, a cholestatic profile with bilirubin and alkaline phosphatase elevation, accompanied by mild AST and ALT elevation, supports congestive hepatopathy. In acute and chronic heart failure, bilirubin, AST, and ALT concentrations are prognostic markers, so trend results with the clinical heart-failure course rather than interpreting them as isolated hepatic disease measures. [5]

Do not use FIB-4 or APRI as reliable surrogates of fibrosis severity in right-sided heart failure: these indices correlate poorly with the degree of hepatic disease in this setting. MELD-XI also correlated only weakly with liver pathology in Fontan patients. [5]
- A cholestatic biochemical pattern in heart failure should prompt assessment for congestion while retaining obstructive and infiltrative etiologies in the differential. [5][10]

*Etiologic branches selected by context and liver-test pattern. [1][5][9][10][15]*

| Clinical context | Expected or concerning test pattern | Actionable next step |
| --- | --- | --- |
| New medication, toxin, supplement, or drug exposure | Hepatocellular, cholestatic, or mixed injury; increasing aminotransferases or bilirubin heightens concern. [1][10] | Review and stop or reconsider the suspected exposure; promptly repeat aminotransferases, bilirubin, and alkaline phosphatase when aminotransferases exceed 3 times the upper limit of normal and/or bilirubin exceeds 2 times the upper limit of normal. [1] |
| Hypotension or hemodynamic compromise | Severe aminotransferase elevation may represent ischemic hepatitis. [10] | Prioritize hemodynamic assessment while evaluating other causes of marked hepatocellular injury. [10] |
| Cardiometabolic risk factors or steatosis on imaging | MASLD may occur with abnormal enzymes or radiologic steatosis. [9][15] | Perform fibrosis risk stratification with FIB-4 followed by transient elastography. [9] |
| Right-sided heart failure | Bilirubin and alkaline phosphatase elevation with mild AST/ALT elevation. [5] | Assess congestion and avoid relying on FIB-4 or APRI to stage congestive hepatic disease. [5] |
| ALT or AST greater than 15 times the upper limit of normal | Severe acute hepatocellular injury. [10] | Evaluate acute viral, toxic or drug-related, ischemic, autoimmune, Wilson, obstructive, and hepatic vascular causes urgently. [10] |

## Use serial testing to detect progression and guide referral

Repeat testing is most valuable when it changes the urgency of exposure management, acute-care triage, or fibrosis staging.

Repeat testing should be prompt, not routine-delay follow-up, when a potential hepatotoxic reaction is accompanied by aminotransferases above 3 times the upper limit of normal or total bilirubin above 2 times the upper limit of normal. Record the local laboratory reference range and make results immediately available to the treating team when testing occurs outside the primary site of care. [1]

For chronic metabolic liver disease, serial aminotransferases do not replace fibrosis risk assessment. Patients with cardiometabolic risk factors, abnormal liver enzymes, or radiologic steatosis should enter a fibrosis-oriented pathway using FIB-4 and transient elastography, because advanced fibrosis predicts liver-related outcomes. [9]

In heart failure, interpret serial bilirubin, AST, and ALT in the hemodynamic context because these values predict mortality in acute and chronic heart failure and may reflect congestion rather than the degree of fixed hepatic fibrosis. [5]
- Escalate from biochemical monitoring to urgent evaluation if repeat testing worsens or symptoms persist after a suspected drug exposure. [1]
- Escalate severe hepatocellular injury beyond routine outpatient workup when aminotransferases exceed 15 times the upper limit of normal. [10]
- Use transient elastography after FIB-4 when MASLD fibrosis staging remains clinically relevant; do not substitute aminotransferase normalization for fibrosis reassessment. [9]

*Monitoring decisions driven by clinical context. [1][5][9][10]*

| Scenario | Monitoring action | What changes management |
| --- | --- | --- |
| Potential drug-induced liver injury | Promptly repeat aminotransferases, total bilirubin, and alkaline phosphatase. [1] | Persistent symptoms or worsening repeat results support urgent reassessment of the exposure and severity. [1] |
| Severe aminotransferase elevation | Do not defer to delayed serial testing alone. [10] | ALT or AST greater than 15 times the upper limit of normal triggers urgent acute-injury evaluation. [10] |
| MASLD risk assessment | Use FIB-4, then transient elastography. [9] | Advanced-fibrosis risk changes the need for liver-focused longitudinal management. [9] |
| Right-sided heart failure | Trend bilirubin, AST, and ALT with decongestion and heart-failure status. [5] | Do not interpret FIB-4 or APRI as validated fibrosis staging tools for congestive hepatopathy. [5] |

## Common questions

### Are liver function tests synonymous with liver enzymes?

No. ALT and AST principally indicate hepatocellular injury, while alkaline phosphatase and bilirubin help identify cholestatic or obstructive processes; prothrombin time and albumin provide information relevant to hepatic synthetic function. [7][10]

### When should abnormal liver tests be repeated urgently after a drug exposure?

Promptly repeat testing when aminotransferases exceed 3 times the upper limit of normal and/or total bilirubin exceeds 2 times the upper limit of normal, especially if symptoms persist, because progression can be rapid in severe drug-induced liver injury. [1]

## References
1. [PDF] Guidance for Industry: Drug-Induced Liver Injury - FDA — www.fda.gov — https://www.fda.gov/media/116737/download
2. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease | Gut — gut.bmj.com — https://gut.bmj.com/content/73/5/825
3. MASLD: a systemic metabolic disorder with cardiovascular and ... - Gut — gut.bmj.com — https://gut.bmj.com/content/73/4/691
4. Exclusion of Liver Disease and Underutilization of Liver-Specific Endpoints in Heart Failure Trials — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jchf.2025.03.036
5. The Cardiohepatic Axis in Heart Failure — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacbts.2025.05.007
6. Acute Liver Failure Associated With Dronedarone | Circulation — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/circep.111.963447
7. Evaluation of Abnormal Liver Biochemical Test Results — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0016508526002398
8. Management of asymptomatic patients with abnormal liver function tests - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0953620525003085
9. EASL Clinical Practice Guidelines on nutrition in chronic liver disease — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0168827818321779
10. AGA technical review on the evaluation of liver chemistry tests - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S001650850200241X
11. Investigative algorithms for disorders affecting... - Ovid — journals.lww.com — https://journals.lww.com/jlpm/fulltext/2024/01000/investigative_algorithms_for_disorders_affecting.7.aspx
12. Metabolic dysfunction–associated steatotic liver... : Hepatology — journals.lww.com — https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000000670~metabolic-dysfunctionassociated-steatotic-liver-disease
13. Metabolic dysfunction-associated steatotic liver... : Singapore Medical Journal — journals.lww.com — https://journals.lww.com/smj/fulltext/9900/metabolic_dysfunction_associated_steatotic_liver.259.aspx
14. Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD ... — www.ccjm.org — https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdci24-0094&link_type=DOI
15. Nonalcoholic Fatty Liver Disease Gets Renamed as Metabolic Dysfunction–Associated Steatotic Liver Disease: Progress But With Challenges - Gastroenterology — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085%2823%2905227-7/fulltext
16. Clinical Care Pathway for the Risk Stratification and Management of ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0016508521033849
17. Does the hepatologist still need to rely on aminotransferases in ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1665268125001243
18. Acute liver failure: A practical update — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2589555924001356
19. Targeting AKT to treat liver disease: Opportunities and challenges - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0006295225004733

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.